The higher case-fatality rate could be because of low resting rates, a greater number of deaths, or both,
The COVID-19 case-fatality rate of among Asian Americans is much higher than the overall population, according to research results reported today in an Health Affairs blog post.
Dr. Lee Newcomer
In San Francisco, Asian Americans have experienced a case-fatality rate of 5.2% compared with 1.3% for the overall population, report a research team at the University of California, San Francisco, that includes Tung Nguyen, M.D., director of the Asian American Research Center on Health, which is in San Francisco.
Other areas of the country also have a higher case-fatality rate among Asian Americans. Here are some of the numbers reported by Nguyen and his colleagues:
The case-fatality rates is the ratio of fatalities to cases, so a high case-fatality rate could be the result of a low testing rate (a smaller denominator) as well as greater number of deaths (a larger numerator). Nguyen and his colleagues note that data from Los Angeles County and Illionois suggest that Asian Americans may be receiving disproportionately low rates of testing.
Socioeconomic factors may play a role. The researchers note that almost 60% of Asian Americans are born outside the U.S. so factors such as health literacy and English proficiency may affect access to care, quality of care, and seeking care later in the illness.
The researchers say that policy makers could help address the Asian American disparity by mandating standardized case and fatality reporting and directing public health agencies to investigate the reasons that particular populations, including Asian Americans, face a seemingly heightened risk of death from COVID-19.
“Importantly, there is no evidence that Asian Americans face a higher case fatality due to ethnicity itself,” the researchers wrote in the blog post. “In comparison, the CFR (case-fatality rate) in Asian countries are substantially lower than those observed among Asian Americans in many US states and counties.”
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More